Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.05
VRX's Cash to Debt is ranked lower than
55% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. VRX: 0.05 )
VRX' s 10-Year Cash to Debt Range
Min: -1.06   Max: No Debt
Current: 0.05

-1.06
No Debt
Equity to Asset 0.19
VRX's Equity to Asset is ranked lower than
52% of the 822 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. VRX: 0.19 )
VRX' s 10-Year Equity to Asset Range
Min: 0.18   Max: 0.85
Current: 0.19

0.18
0.85
F-Score: 7
Z-Score: 1.70
M-Score: -2.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 20.21
VRX's Operating margin (%) is ranked higher than
90% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. VRX: 20.21 )
VRX' s 10-Year Operating margin (%) Range
Min: -9.32   Max: 45.51
Current: 20.21

-9.32
45.51
Net-margin (%) 6.23
VRX's Net-margin (%) is ranked higher than
73% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. VRX: 6.23 )
VRX' s 10-Year Net-margin (%) Range
Min: -47.86   Max: 54.96
Current: 6.23

-47.86
54.96
ROE (%) 9.91
VRX's ROE (%) is ranked higher than
81% of the 879 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.98 vs. VRX: 9.91 )
VRX' s 10-Year ROE (%) Range
Min: -59.65   Max: 88.03
Current: 9.91

-59.65
88.03
ROA (%) 1.82
VRX's ROA (%) is ranked higher than
68% of the 913 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.21 vs. VRX: 1.82 )
VRX' s 10-Year ROA (%) Range
Min: -18.92   Max: 47.04
Current: 1.82

-18.92
47.04
ROC (Joel Greenblatt) (%) 64.89
VRX's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.70 vs. VRX: 64.89 )
VRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -50.66   Max: 291.4
Current: 64.89

-50.66
291.4
Revenue Growth (%) 46.50
VRX's Revenue Growth (%) is ranked higher than
96% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. VRX: 46.50 )
VRX' s 10-Year Revenue Growth (%) Range
Min: -10.8   Max: 82.1
Current: 46.5

-10.8
82.1
EBITDA Growth (%) 113.00
VRX's EBITDA Growth (%) is ranked higher than
99% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.30 vs. VRX: 113.00 )
VRX' s 10-Year EBITDA Growth (%) Range
Min: -35.7   Max: 113
Current: 113

-35.7
113
EPS Growth (%) 39.00
VRX's EPS Growth (%) is ranked higher than
92% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. VRX: 39.00 )
VRX' s 10-Year EPS Growth (%) Range
Min: -37.2   Max: 100.6
Current: 39

-37.2
100.6
» VRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

VRX Guru Trades in Q4 2013

Jim Simons 364,189 sh (New)
Lee Ainslie 1,633,838 sh (New)
Diamond Hill Capital 4,675 sh (+27.21%)
Pioneer Investments 7,300 sh (unchged)
Jeff Ubben 18,923,877 sh (unchged)
Jean-Marie Eveillard 902,742 sh (unchged)
Julian Robertson Sold Out
Lou Simpson 1,658,555 sh (-0.14%)
Steve Mandel 7,756,485 sh (-0.32%)
Mariko Gordon 44,702 sh (-0.59%)
Ruane Cunniff 34,305,656 sh (-0.99%)
Louis Moore Bacon 4,706 sh (-3.57%)
Andreas Halvorsen 8,329,004 sh (-6.93%)
Glenn Greenberg 6,113,227 sh (-7%)
Wallace Weitz 1,849,200 sh (-9.48%)
Chuck Royce 4,600 sh (-11.54%)
Jeremy Grantham 248,074 sh (-12.75%)
Chris Davis 97,534 sh (-15.59%)
Private Capital 369,896 sh (-34.92%)
Steven Cohen 2,214 sh (-58.23%)
» More
Q1 2014

VRX Guru Trades in Q1 2014

George Soros 165,411 sh (New)
Daniel Loeb 250,000 sh (New)
John Paulson 1,000,000 sh (New)
Chris Davis 2,718,162 sh (+2686.89%)
Diamond Hill Capital 29,370 sh (+528.24%)
Steven Cohen 8,334 sh (+276.42%)
Louis Moore Bacon 7,544 sh (+60.31%)
Lee Ainslie 2,421,778 sh (+48.23%)
Steve Mandel 8,816,702 sh (+13.67%)
Andreas Halvorsen 9,296,143 sh (+11.61%)
Jeff Ubben 18,923,877 sh (unchged)
Pioneer Investments 7,300 sh (unchged)
Chuck Royce Sold Out
Jean-Marie Eveillard 902,542 sh (-0.02%)
Ruane Cunniff 34,217,366 sh (-0.26%)
Lou Simpson 1,614,593 sh (-2.65%)
Glenn Greenberg 5,592,558 sh (-8.52%)
Wallace Weitz 1,597,540 sh (-13.61%)
Private Capital 303,536 sh (-17.94%)
Jeremy Grantham 152,647 sh (-38.47%)
Mariko Gordon 24,276 sh (-45.69%)
Jim Simons 47,189 sh (-87.04%)
» More
Q2 2014

VRX Guru Trades in Q2 2014

Joel Greenblatt 6,172 sh (New)
Louis Moore Bacon 127,422 sh (+1589.05%)
Diamond Hill Capital 147,867 sh (+403.46%)
George Soros 472,187 sh (+185.46%)
Andreas Halvorsen 11,830,932 sh (+27.27%)
Chris Davis 3,153,748 sh (+16.03%)
Steve Mandel 10,089,450 sh (+14.44%)
Jean-Marie Eveillard 1,024,402 sh (+13.5%)
Lee Ainslie 2,625,014 sh (+8.39%)
Glenn Greenberg 6,050,442 sh (+8.19%)
Ruane Cunniff 34,298,384 sh (+0.24%)
Lou Simpson 1,615,549 sh (+0.06%)
Steven Cohen 1,528,606 sh (unchged)
Jeff Ubben 18,923,877 sh (unchged)
Jim Simons Sold Out
Mariko Gordon Sold Out
Daniel Loeb Sold Out
Pioneer Investments Sold Out
Private Capital 300,446 sh (-1.02%)
Wallace Weitz 1,551,076 sh (-2.91%)
John Paulson 500,300 sh (-49.97%)
Jeremy Grantham 45,552 sh (-70.16%)
» More
Q3 2014

VRX Guru Trades in Q3 2014

Paul Tudor Jones 6,826 sh (New)
George Soros 626,748 sh (+32.73%)
Diamond Hill Capital 173,012 sh (+17.01%)
Lou Simpson 1,815,916 sh (+12.4%)
Chris Davis 3,529,237 sh (+11.91%)
Wallace Weitz 1,691,525 sh (+9.05%)
Steve Mandel 10,985,940 sh (+8.89%)
Glenn Greenberg 6,586,582 sh (+8.86%)
John Paulson 520,700 sh (+4.08%)
Ruane Cunniff 34,494,015 sh (+0.57%)
Steven Cohen 523,400 sh (unchged)
Jeff Ubben 18,923,877 sh (unchged)
Joel Greenblatt Sold Out
Private Capital 296,871 sh (-1.19%)
Jean-Marie Eveillard 1,010,802 sh (-1.33%)
Lee Ainslie 2,527,896 sh (-3.7%)
Andreas Halvorsen 9,967,690 sh (-15.75%)
Steven Cohen 1,056,700 sh (-30.87%)
Jeremy Grantham 23,705 sh (-47.96%)
Louis Moore Bacon 30,544 sh (-76.03%)
» More
» Details

Insider Trades

Latest Guru Trades with VRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Glenn Greenberg 2014-09-30 Add 8.86%2.6%$106.73 - $130.26 $ 14018%6586582
Andreas Halvorsen 2014-09-30 Reduce -15.75%1.02%$106.73 - $130.26 $ 14018%9967690
Lou Simpson 2014-09-30 Add 12.4%1.01%$106.73 - $130.26 $ 14018%1815916
Wallace Weitz 2014-09-30 Add 9.05%0.54%$106.73 - $130.26 $ 14018%1691525
Steve Mandel 2014-09-30 Add 8.89%0.46%$106.73 - $130.26 $ 14018%10985940
Lee Ainslie 2014-09-30 Reduce -3.7%0.18%$106.73 - $130.26 $ 14018%2527896
George Soros 2014-09-30 Add 32.73%0.15%$106.73 - $130.26 $ 14018%626748
Chris Davis 2014-09-30 Add 11.91%0.15%$106.73 - $130.26 $ 14018%3529237
Ruane Cunniff 2014-09-30 Add 0.57%0.14%$106.73 - $130.26 $ 14018%34494015
Joel Greenblatt 2014-09-30 Sold Out 0.01%$106.73 - $130.26 $ 14018%0
Glenn Greenberg 2014-06-30 Add 8.19%2.33%$116.99 - $138.13 $ 14010%6050442
Andreas Halvorsen 2014-06-30 Add 27.27%1.39%$116.99 - $138.13 $ 14010%11830932
Steve Mandel 2014-06-30 Add 14.44%0.64%$116.99 - $138.13 $ 14010%10089450
Daniel Loeb 2014-06-30 Sold Out 0.48%$116.99 - $138.13 $ 14010%0
Lee Ainslie 2014-06-30 Add 8.39%0.37%$116.99 - $138.13 $ 14010%2625014
John Paulson 2014-06-30 Reduce -49.97%0.32%$116.99 - $138.13 $ 14010%500300
George Soros 2014-06-30 Add 185.46%0.29%$116.99 - $138.13 $ 14010%472187
Wallace Weitz 2014-06-30 Reduce -2.91%0.19%$116.99 - $138.13 $ 14010%1551076
Chris Davis 2014-06-30 Add 16.03%0.17%$116.99 - $138.13 $ 14010%3153748
Mariko Gordon 2014-06-30 Sold Out 0.13%$116.99 - $138.13 $ 14010%0
Joel Greenblatt 2014-06-30 New Buy0.01%$116.99 - $138.13 $ 14010%6172
Glenn Greenberg 2014-03-31 Reduce -8.52%2.5%$112.62 - $148 $ 1403%5592558
Lee Ainslie 2014-03-31 Add 48.23%1.46%$112.62 - $148 $ 1403%2421778
Wallace Weitz 2014-03-31 Reduce -13.61%0.99%$112.62 - $148 $ 1403%1597540
Private Capital 2014-03-31 Reduce -17.94%0.97%$112.62 - $148 $ 1403%303536
Chris Davis 2014-03-31 Add 2686.89%0.95%$112.62 - $148 $ 1403%2718162
John Paulson 2014-03-31 New Buy0.65%$112.62 - $148 $ 1403%1000000
Steve Mandel 2014-03-31 Add 13.67%0.61%$112.62 - $148 $ 1403%8816702
Andreas Halvorsen 2014-03-31 Add 11.61%0.53%$112.62 - $148 $ 1403%9296143
Daniel Loeb 2014-03-31 New Buy0.48%$112.62 - $148 $ 1403%250000
Lou Simpson 2014-03-31 Reduce -2.65%0.25%$112.62 - $148 $ 1403%1614593
George Soros 2014-03-31 New Buy0.22%$112.62 - $148 $ 1403%165411
Mariko Gordon 2014-03-31 Reduce -45.69%0.1%$112.62 - $148 $ 1403%24276
Julian Robertson 2013-12-31 Sold Out 2.5%$103.04 - $117.42 $ 14028%0
Lee Ainslie 2013-12-31 New Buy2.5%$103.04 - $117.42 $ 14028%1633838
Glenn Greenberg 2013-12-31 Reduce -7%2.16%$103.04 - $117.42 $ 14028%6113227
Private Capital 2013-12-31 Reduce -34.92%1.89%$103.04 - $117.42 $ 14028%369896
Wallace Weitz 2013-12-31 Reduce -9.48%0.76%$103.04 - $117.42 $ 14028%1849200
Andreas Halvorsen 2013-12-31 Reduce -6.93%0.36%$103.04 - $117.42 $ 14028%8329004
Ruane Cunniff 2013-12-31 Reduce -0.99%0.21%$103.04 - $117.42 $ 14028%34305656
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Valeant Pharmaceuticals International Inc

Diamond Hill Capital Comments on Valeant Pharmaceuticals International Inc - Jul 25, 2014

We initiated a position in Valeant Pharmaceuticals International, Inc., (VRX) a specialty pharmaceutical company that is a leader in eye care and dermatology. Unlike most in the pharmaceutical space, Valeant has a very lean cost structure and a much more targeted focus for internal research and development. Instead, the company has been very successful in acquiring proven products. Management is among the best in the business, making every decision through the lens of shareholder value creation.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Sequoia Fund's Discussion of Valeant Pharmaceuticals - Mar 07, 2014

Our largest holding, Valeant, had an outstanding year. Full year numbers have not been reported yet, but we believe that cash earnings per share should exceed $6, well ahead of last year’s result. The big news of the year was the acquisition of Bausch & Lomb for nearly $9 billion in August. The deal should be highly accretive and, together with modest organic growth in its other operations, enable cash earnings per share to increase significantly in 2014. The integration of Bausch & Lomb appears on track with cost synergies, originally estimated by management at around $800 million, now expected to be over $850 million.



Cash earnings per share have probably more than tripled over the last four years. While we do not expect this growth trajectory to continue at such a rapid pace in the future, we do believe the company can continue to produce positive organic growth supplemented by ongoing acquisitions that will enable Valeant to grow cash earnings per share at an above-average rate.



We like Valeant’s approach to the pharmaceutical business. It has acquired a diverse stable of branded, generic and OTC drugs and, more recently, medical devices including dermal fillers and contact lenses. Many of its products are steady sellers in specialty categories like dermatology and ophthalmology. In our view, Valeant is essentially a value investor in health care products.





Source: Sequoia Fund's 2013 Annual Report - Management's Discussion of Fund Performance



Check out Sequoia Fund latest stock trades

Wallace Weitz Comments on Valeant Pharmaceuticals - Jul 15, 2013

Valeant (VRX--$86)(VRX) Valeant Pharmaceuticals continues to make acquisitions (most recently agreeing to purchase Bausch and Lomb), wring cost savings from the combined operations, and grow earnings per share. The outlook for Valeant’s well-diversified portfolio of 1,100 products is relatively predictable. The company has a robust pipeline of acquisition candidates and we expect Valeant to build on its dermatology and eye care franchises over the next few years.

From Wallace Weitz’s second quarter 2013 letter to shareholders.


Check out Wallace Weitz latest stock trades

Top Ranked Articles about Valeant Pharmaceuticals International Inc

Former Warren Buffett CIO Lou Simpson Buys Liberty Global, Valeant, U.S. Bancorp, Sells TE Connectivity
If you don’t know Lou Simpson (Trades, Portfolio), you should. He was the former investment manager at GEICO and Warren Buffett (Trades, Portfolio) spoke highly about him many times. Mr. Simpson just reported his third quarter portfolio. He buys Liberty Global PLC, Valeant Pharmaceuticals International Inc, U.S. Bancorp, Charles Schwab Corp, Brookfield Asset Management Inc, Oracle Corporation, Wells Fargo & Co, Berkshire Hathaway Inc, Crown Holdings Inc, sells TE Connectivity Ltd during the 3-months ended 09/30/2014, according to the most recent filings of his investment company, SQ Advisors, LLC. As of 09/30/2014, SQ Advisors, LLC owns 13 stocks with a total value of $2.6 billion. These are the details of the buys and sells. Read more...
Most Held Canadian Stocks of the Second Quarter
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which companies based in Canada were held by the highest number of gurus. The following five companies come from a variety of industries, are Canadian-based and are held by the largest number of gurus. Read more...
Diamond Hill Capital Comments on Valeant Pharmaceuticals International Inc
We initiated a position in Valeant Pharmaceuticals International, Inc., (VRX) a specialty pharmaceutical company that is a leader in eye care and dermatology. Unlike most in the pharmaceutical space, Valeant has a very lean cost structure and a much more targeted focus for internal research and development. Instead, the company has been very successful in acquiring proven products. Management is among the best in the business, making every decision through the lens of shareholder value creation. Read more...
Bill Ackman and Valeant Pharmaceuticals Team Up to Take Over Pharmaceutical Company Allergen
Over the past week GuruFocus Real Time Picks reported that Bill Ackman (Trades, Portfolio) made a buy into Allergen (AGN). This is the first buy into the company for Ackman, and he did so in a big way by purchasing a total of 28,878,538 shares of the company’s stock. He bought these shares at the average price of $120.89 per share on April 11, and since this buy the price per share is up 35% to $163.65. Read more...
Top Guru-Held Canadian Stocks
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which companies based in Canada were held by the highest number of gurus. The following five companies come from a variety of industries, are Canadian-based and are held by the largest number of gurus. Read more...
Sequoia Fund Comments on Valeant Pharmaceuticals, Advance Auto Parts, Berkshire Hathaway, and Precision Castparts
Sequoia benefited greatly from two transformative acquisitions announced in 2013: Valeant’s purchase of Bausch & Lomb and Advance Auto Parts’ purchase of General Parts International. Both deals were game changers which will significantly increase these two companies’ earnings beginning in 2014. While we’ve long been partial to companies that can grow organically, Sequoia’s returns have been boosted considerably by companies that may have limited organic growth opportunities but have done smart serial acquisitions, such as Valeant Pharmaceuticals and Berkshire Hathaway. Precision Castparts has been another serial acquirer that has created great value for shareholders. Read more...
Sequoia Fund's Discussion of Valeant Pharmaceuticals
Our largest holding, Valeant, had an outstanding year. Full year numbers have not been reported yet, but we believe that cash earnings per share should exceed $6, well ahead of last year’s result. The big news of the year was the acquisition of Bausch & Lomb for nearly $9 billion in August. The deal should be highly accretive and, together with modest organic growth in its other operations, enable cash earnings per share to increase significantly in 2014. The integration of Bausch & Lomb appears on track with cost synergies, originally estimated by management at around $800 million, now expected to be over $850 million. Read more...
Weekly CEO Buys Highlight: KMI, VRX, CLMS, OPK, TLOG
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 101.30
VRX's P/E(ttm) is ranked higher than
69% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.60 vs. VRX: 101.30 )
VRX' s 10-Year P/E(ttm) Range
Min: 5.91   Max: 661.18
Current: 101.3

5.91
661.18
P/B 9.65
VRX's P/B is ranked higher than
54% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. VRX: 9.65 )
VRX' s 10-Year P/B Range
Min: 1.03   Max: 9.96
Current: 9.65

1.03
9.96
P/S 5.91
VRX's P/S is ranked higher than
64% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. VRX: 5.91 )
VRX' s 10-Year P/S Range
Min: 1.61   Max: 8.8
Current: 5.91

1.61
8.8
PFCF 37.39
VRX's PFCF is ranked higher than
87% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. VRX: 37.39 )
VRX' s 10-Year PFCF Range
Min: 2.67   Max: 281.44
Current: 37.39

2.67
281.44
EV-to-EBIT 39.88
VRX's EV-to-EBIT is ranked higher than
74% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.43 vs. VRX: 39.88 )
VRX' s 10-Year EV-to-EBIT Range
Min: -5795.6   Max: 2482.6
Current: 39.88

-5795.6
2482.6
PEG 2.45
VRX's PEG is ranked higher than
89% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. VRX: 2.45 )
VRX' s 10-Year PEG Range
Min: 0.76   Max: 249.44
Current: 2.45

0.76
249.44
Current Ratio 1.40
VRX's Current Ratio is ranked higher than
57% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. VRX: 1.40 )
VRX' s 10-Year Current Ratio Range
Min: 0.72   Max: 9.68
Current: 1.4

0.72
9.68
Quick Ratio 1.11
VRX's Quick Ratio is ranked higher than
58% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. VRX: 1.11 )
VRX' s 10-Year Quick Ratio Range
Min: 0.59   Max: 9.3
Current: 1.11

0.59
9.3

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 4.18
VRX's Price/DCF (Projected) is ranked higher than
81% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. VRX: 4.18 )
VRX' s 10-Year Price/DCF (Projected) Range
Min: 0.33   Max: 11.22
Current: 4.18

0.33
11.22
Price/Median PS Value 1.61
VRX's Price/Median PS Value is ranked higher than
63% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. VRX: 1.61 )
VRX' s 10-Year Price/Median PS Value Range
Min: 0.52   Max: 8.58
Current: 1.61

0.52
8.58
Price/Peter Lynch Fair Value 4.05
VRX's Price/Peter Lynch Fair Value is ranked higher than
88% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. VRX: 4.05 )
VRX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.69   Max: 61.66
Current: 4.05

0.69
61.66
Earnings Yield (Greenblatt) 2.50
VRX's Earnings Yield (Greenblatt) is ranked higher than
73% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. VRX: 2.50 )
VRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 20.6
Current: 2.5

0.1
20.6
Forward Rate of Return (Yacktman) 49.99
VRX's Forward Rate of Return (Yacktman) is ranked higher than
98% of the 496 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.85 vs. VRX: 49.99 )
VRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.5   Max: 52.1
Current: 49.99

2.5
52.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:VRX.Canada, BVF.Germany,
Valeant Pharmaceuticals International Inc was formed on 29th March, 1994 and was formerly known as Biovail Corporation. It is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a range of branded, generic and branded generic pharmaceuticals, over-the-counter products "OTC", and medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices, which are marketed directly or indirectly in over 100 countries. The Company operates in two segments; Developed Markets and Emerging Markets. In the Developed Markets segment, it focuses its efforts in the eye health, dermatology, and neurology therapeutic classes. The Developed Markets segment consists of four reporting units based on geography, namely; U.S., Canada and Australia, Western Europe, and Japan. In the Emerging Markets segment, it focuses on branded generics, OTC products, and medical devices. The Emerging Markets segment consists of three reporting units based on geography, namely; Central & Eastern Europe, Middle East and North Africa, Latin America, and Asia & South Africa. Its principal pharmaceutical products are; Wellbutrin XL, Xenazine, Zovirax Cream, Zovirax, Lotemax, Arestin and Prolensa. Its principal OTC products are; PreserVision, ReNu Multiplus, Ocuvite, Artelac, and CeraVe. The Company relies on a combination of contractual provisions, confidentiality policies and procedures and patent, trademark, copyright and trade secrecy laws to protect the proprietary aspects of its technology and business. Its top four geographic markets are; the U.S. and Puerto Rico, Canada, Poland and Russia. The Company competes with specialty and other pharmaceutical companies, medical device companies, biotechnology companies, OTC companies and generic manufacturers, in the U.S., Canada, the EU and in other countries in which it market its products. The principal raw materials, including active pharmaceutical ingredient, used by the Company "or its third party manufacturers" for its various products are purchased in the open market or are otherwise available from several sources. The Company is subject to extensive U.S. federal and state health care marketing and fraud and abuse regulations, such as the federal False Claims Act, federal and provincial marketing regulation in Canada and similar regulations in foreign countries in which it may conduct its business.
» More Articles for VRX

Headlines

Articles On GuruFocus.com
Wallace Weitz Buys Discovery Communications, Sells Apple in Q3 Nov 14 2014 
Former Warren Buffett CIO Lou Simpson Buys Liberty Global, Valeant, U.S. Bancorp, Sells TE Connectiv Nov 14 2014 
Ackman’s Pershing Group Buys Stake in Zoetis Nov 13 2014 
Valeant Part XIII: channeling Jeff Skilling - or trying to reconstruct Valeant's balance sheet Oct 30 2014 
Wallace Weitz's Partners Value Fund Q3 2014 Commentary Oct 16 2014 
Ackman's Pershing Square Now Available To The Public Oct 13 2014 
Bill Ackman and Valeant Could Sweeten Allergan Deal By $15 A Share Oct 10 2014 
Wallace Weitz's Value Fund Q2 Commentary Oct 06 2014 
Transcript of Ruane, Cunniff & Goldfarb Investor Day - May 16, 2014 Oct 05 2014 
Most Held Canadian Stocks of the Second Quarter Sep 04 2014 


More From Other Websites
Business Highlights Dec 17 2014
Great Stocks: Valeant Pharmaceuticals Near Buy Point Dec 16 2014
Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance Dec 15 2014
Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance Dec 15 2014
Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance Dec 15 2014
Nestlé Chief Paul Bulcke Takes a Global View Dec 13 2014
Shire Updates on Pipeline at Research & Development Day Dec 11 2014
JAZZ Pharmaceuticals Slips After Dosing Issue on JZP-386 Dec 10 2014
Herb Greenberg: What's Next for Valeant After Its Botched Bid for Allergan Dec 10 2014
Zoetis Inc. Spikes Briefly On Remarks From Sanofi CEO Dec 09 2014
UCB Reports Phase III Data on Epilepsy Drug, To File in 2015 Dec 09 2014
Where Could ValueAct Capital's New $1.5 Billion Go? Dec 09 2014
Stock Market Today: Wall Street Drops; Conn's Down 40% Dec 09 2014
Valeant puts dealmaking on hold to focus on the bottom line Dec 09 2014
Will Valeant Pharmaceuticals (VRX) Stock be Helped Today by New Strategy? Dec 09 2014
December 9 Premarket Briefing: 10 Things You Should Know Dec 09 2014
Two Gauges That Point To Fund Buying In A Stock Dec 08 2014
Novartis (NVS) Presents Additional Data on Leukemia Drug Dec 08 2014
Inside The IBD 50: Challenging Time For Growth Stocks Dec 05 2014
Roche to Acquire California-based Ariosa Diagnostics Dec 05 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK